Governance
Investors

Publications

2025

Tripokin: A multi-specific immunocytokine for cancer immunotherapy.

Prodi et al., Int J Cancer. 2025 Jan 1;156(1):216-228

 

Designing drugs with reversible activity.

Neri D. Nat Biotechnol. 2025 Feb;43(2):177-178

 

Intratumoral administration of daromun in non-melanoma skin cancer: Preliminary results from a phase 2 non-randomized controlled trial.

Flatz et al., J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e147-e149

 

PSMA-targeted Small Molecule-Drug Conjugates based on a Post-Prolyl Peptidase Cleavable Linker for the Treatment of Prostate Cancer.

Georgiev et al., Mol Cancer Ther. 2025 Mar 4

 

Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice.

Carbone et al., J Exp Clin Cancer Res. 2025 Jan 7;44(1):7

 

Flexibility-tuning of dual-display DNA-encoded chemical libraries facilitates cyclic peptide ligand discovery.

Petrov et al., Nat Commun. 2025 Apr 5;16(1):3273

 

Effect of molar dose on the in vivo tissue biodistribution profile of FAP-targeted radioligand therapeutics.

Galbiati et al., Eur J Nucl Med Mol Imaging. 2025 Mar;52(4):1399-1405

 

Delivery of Monomethyl Auristatin F to the Tumor Microenvironment with Noninternalizing Fibroblast Activation Protein-Cleavable Small Molecule-Drug Conjugates Elicits Potent In Vivo Anticancer Activity.

Bocci et al., Bioconjug Chem. 2025 Jan 15;36(1):15-19

 

Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein.

Rotta et al., J Immunother Cancer. 2025 May 11;13(5):e010831

 

Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer.

Hachey et al., J Nucl Med. 2025 Apr 17:jnumed.124.268859

 

Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy.

Georgiev et al., Nat Biomed Eng. 2025 Jun 26

 

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Kähler et al., Ann Oncol. 2025 Jul 7:S0923-7534(25)00829-4

 

Small Organic Carbonic Anhydrase IX Ligands from DNA-Encoded Chemical Libraries for Tumor-Targeted Delivery of Radionuclides.

Müller et al., J Am Chem Soc. 2025 May 28;147(21):18230-18239

 

Development of multivalent FAP-targeted Small Molecule-Drug Conjugates with tailored MMAE release kinetics.

Bocci et al., Mol Cancer Ther. 2025 Jun 30

 

Past, present and future of drug conjugates for cancer therapy.

Cazzamalli et al., Nat Cancer. 2025 Sep 11

 

Phenylalanine-Based DNA-Encoded Chemical Libraries for the Discovery of Potent and Selective Small Organic Ligands Against Markers of Cancer and Immune Cells.

Migliorini et al., Adv Sci (Weinh). 2025 Jun 29:e05351

 

A comparative analysis of tumor markers reveals EDA fibronectin as a promising target in high-grade serous ovarian cancer.

Piermattei et al., J Ovarian Res. 2025 Aug 26;18(1):194

 

2024

A single-chain variable fragment-based bispecific T-cell activating antibody against CD117 enables T-cell mediated lysis of acute myeloid leukemia and hematopoietic stem and progenitor cells.

Volta et al., Hemasphere. 2024 Nov 19;8(11):e70055

 

Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors.

Pellegrino et al., Oncoimmunology. 2024 Oct 3;13(1):2412371

 

Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells.

Volta et al., Leukemia. 2024 Sep 18.

 

Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors.

Galbiati et al., J Nucl Med. 2024 Oct 1;65(10):1604-1610

 

Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy.

Prodi E et al., Onco Targets Ther. 2024 Aug 29;17:697-715

 

Tripokin: A multi-specific immunocytokine for cancer immunotherapy.

Prodi et al., Int J Cancer. 2024 Aug 23

 

An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade.

Di Nitto et al., J Immunother Cancer. 2024 Aug 13;12(8):e008504

 

Molecular Evolution of Multivalent OncoFAP Derivatives with Enhanced Tumor Uptake and Prolonged Tumor Retention.

Galbiati et al., J Med Chem. 2024 Aug 8;67(15):13392-13408

 

Extra domain A-containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody.

Singerer et al., Cardiovasc Res. 2024 Oct 14;120(12):1485-1497

 

Permutational Encoding Strategy Accelerates HIT Validation from Single-Stranded DNA-Encoded Libraries.

Puglioli S et al., Bioconjug Chem. 2024 Jul 17;35(7):1033-1043

 

Intratumoral administration of daromun in non-melanoma skin cancer: Preliminary results from a phase 2 non-randomized controlled trial.

Flatz et al., J Eur Acad Dermatol Venereol. 2024 Jun 22

 

Cytokine Biopharmaceuticals with “Activity-on-Demand” for Cancer Therapy.

Rotta et al., Bioconjug Chem. 2024 Aug 21;35(8):1075-1088

 

Highly pure DNA-encoded chemical libraries by dual-linker solid-phase synthesis.

Keller et al., Science. 2024 Jun 14;384(6701):1259-1265

 

DNA-encoded chemical libraries enable the discovery of potent PSMA-ligands with substantially reduced affinity towards the GCPIII anti-target.

Lucaroni et al., Chem Sci. 2024 Apr 2;15(18):6789-6799

 

Discovery of Glutamate Carboxypeptidase III Ligands to Compete the Uptake of [177Lu]Lu-PSMA-617 in Healthy Organs.

Müller et al., J Med Chem. 2024 May 23;67(10):8247-8260

 

Designing drugs with reversible activity.

Neri, Nat Biotechnol. 2024 Apr 30

 

Optimizing the Design and Geometry of T Cell-Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer.

Elsayed et al., Mol Cancer Ther. 2024 Jul 2;23(7):1010-1020

 

Targeted interleukin-2 enhances the in vivo anti-cancer activity of Pluvicto™.

Georgiev et al., Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2332-2337

 

A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors.

Rotta et al., EMBO Mol Med. 2024 Apr;16(4):904-926

 

In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment.

Bocci et al., J Control Release. 2024 Mar;367:779-790

 

Expression of Inflammatory Genes in Murine Lungs in a Model of Experimental Pulmonary Hypertension: Effects of an Antibody-Based Targeted Delivery of Interleukin-9.

Heiss et al., Adv Respir Med. 2024 Jan 3;92(1):27-35

 

Control of the antitumour activity and specificity of CAR T cells via organic adapters covalently tethering the CAR to tumour cells.

Stepanov et al., Nat Biomed Eng. 2024 May;8(5):529-543

2023

Ex vivo mass spectrometry-based biodistribution analysis of an antibody-Resiquimod conjugate bearing a protease-cleavable and acid-labile linker.

Bisbal Lopez et al., Front Pharmacol. 2023 Dec 6;14:1320524

 

Impact of library input on the hit discovery rate in DNA-encoded chemical library selections.

Puglioli et al., Chem Sci. 2023 Oct 17;14(43):12026-12033

 

Adapting Neutralizing Antibodies to Viral Variants by Structure-Guided Affinity Maturation Using Phage Display Technology.

Peissert et all., Glob Chall. 2023 Aug 21;7(10):2300088

 

Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics.

Galbiati et al., J Nucl Med. 2023 Dec 1;64(12):1934-1940

 

Structural insights into the interaction of three Y-shaped ligands with PI3Kα.

Zhou et al., Proc Natl Acad Sci U S A. 2023 Aug 22;120(34):e2304071120

 

Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells.

Magnani et al., Mol Ther Oncolytics. 2023 Jul 19;30:56-71

 

Deep Learning Approach for the Discovery of Tumor-Targeting Small Organic Ligands from DNA-Encoded Chemical Libraries.

Torng et al., ACS Omega. 2023 Jul 6;8(28):25090-25100

 

A DNA-encoded chemical library based on chiral 4-amino-proline enables stereospecific isozyme-selective protein recognition.

Oehler et al., Nat Chem. 2023 Oct;15(10):1431-1443

 

A Comparative Analysis of Fibroblast Activation Protein-Targeted Small Molecule-Drug, Antibody-Drug, and Peptide-Drug Conjugates.

Zana et al., Bioconjug Chem. 2023 Jul 19;34(7):1205-1211

 

Response to: GCP III is not the “off-target” for urea-based PSMA-ligands.

Bassi et al., Eur J Nucl Med Mol Imaging. 2023 Aug;50(10):2947-2949

 

 

Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties.

Elsayed et al., MAbs. 2023 Jan-Dec;15(1):2220839

 

Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen.

Plüss et al., MAbs. 2023 Jan-Dec;15(1):2217964

 

Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma.

Look et al., Sci Transl Med. 2023 May 24;15(697):eadf2281

 

An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions.

Prodi et al., Antibodies (Basel). 2023 Apr 14;12(2):29

 

An Engineered IFNγ-Antibody Fusion Protein with Improved Tumor-Homing Properties.

Di Nitto et al., Pharmaceutics. 2023 Jan 22;15(2):377

 

Promotion of Lymphangiogenesis by Targeted Delivery of VEGF-C Improves Diabetic Wound Healing.

Brunner et al., Cells. 2023 Feb 1;12(3):472

 

 Targeted Interleukin-9 delivery in pulmonary hypertension: Comparison of immunocytokine formats and effector cell study.

Heiss et al., Eur J Clin Invest. 2023 Mar;53(3):e13907

 

Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics.

Lucaroni et al., Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):957-961

2022

Antibody-Mediated Delivery of VEGF-C Promotes Long-Lasting Lymphatic Expansion That Reduces Recurrent Inflammation.

Cousin et al., Cells. 2022 Dec 31;12(1):172

 

Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia.

Bäumer et al., J Hematol Oncol. 2022 Dec 1;15(1):171

Selection of a PD-1 blocking antibody from a novel fully human phage display library.

Peissert et al., Protein Sci. 2022 Dec;31(12):e4486

 

Fibroblast Activation Protein Triggers Release of Drug Payload from Non-internalizing Small Molecule Drug Conjugates in Solid Tumors.

Zana et al., Clin Cancer Res. 2022 Dec 15;28(24):5440-5454

 

Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody.

Nadal et al., J Immunother Cancer. 2022 Sep;10(9):e005282

 

Automated Radiosynthesis, Preliminary In Vitro/In Vivo Characterization of OncoFAP-Based Radiopharmaceuticals for Cancer Imaging and Therapy.

Bartoli et al., Pharmaceuticals (Basel). 2022 Aug 2;15(8):958

 

Isolation of a Natural Killer Group 2D Small-Molecule Ligand from DNA-Encoded Chemical Libraries.

Dakhel et al., ChemMedChem. 2022 Nov 4;17(21):e202200350

 

Mass Spectrometry-Based Method for the Determination of the Biodistribution of Tumor-Targeting Small Molecule-Metal Conjugates.

Gilardoni et al., Anal Chem. 2022 Aug 2;94(30):10715-10721

 

Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade.

Hooper et al., Mol Cancer Ther. 2022 Sep 6;21(9):1462-1472

 

A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake.

Galbiati et al., J Nucl Med. 2022 Dec;63(12):1852-1858

 

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.

Berdel et al., Blood Adv. 2022 Jun 28;6(12):3684-3696

 

Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21.

Di Nitto et al., Antibodies (Basel). 2022 Mar 4;11(1):19

 

Targeted siRNA nanocarrier: a platform technology for cancer treatment.

Bäumer et al., Oncogene. 2022 Apr;41(15):2210-2224

 

Universal encoding of next generation DNA-encoded chemical libraries.

Plais et al., Chem Sci. 2022 Jan 11;13(4):967-974

2021

Identification and Validation of New Interleukin-2 Ligands Using DNA-Encoded Libraries.

Gironda-Martínez et al., J Med Chem. 2021 Dec 9;64(23):17496-17510

 

Modular assembly and encoding strategies for dual-display DNA-encoded chemical libraries.

Oehler S et al., Chem Commun (Camb). 2021 Nov 19;57(92):12289-12292

 

Specific Inhibitor of Placental Alkaline Phosphatase Isolated from a DNA-Encoded Chemical Library Targets Tumor of the Female Reproductive Tract.

Bassi et al., J Med Chem. 2021 Nov 11;64(21):15799-15809

 

An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease.

Dakhel et al., Int J Mol Sci. 2021 Sep 16;22(18):10020

 

DNA-Encoded Chemical Libraries: A Comprehensive Review with Succesful Stories and Future Challenges.

Gironda-Martínez et al., ACS Pharmacol Transl Sci. 2021 Jun 14;4(4):1265-1279

 

An antibody-based enzymatic therapy for cancer treatment: The selective localization of D-amino acid oxidase to EDA fibronectin.

Rosini et al., Nanomedicine. 2021 Aug;36:102424

 

Large screening of DNA-compatible reaction conditions for Suzuki and Sonogashira cross-coupling reactions and for reverse amide bond formation.

Favalli et al., Bioorg Med Chem. 2021 Jul 1;41:116206

 

Affinity Selections of DNA-Encoded Chemical Libraries on Carbonic Anhydrase IX-Expressing Tumor Cells Reveal a Dependence on Ligand Valence.

Oehler et al., Chemistry. 2021 Jun 21;27(35):8985-8993

 

Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.

Schliemann et al., Eur J Cancer. 2021 Jun;150:143-154

 

An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications.

Millul et al., Proc Natl Acad Sci U S A. 2021 Apr 20;118(16):e2101852118

 

Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications.

Favalli et al., Nat Chem. 2021 Jun;13(6):540-548

 

Therapeutic Evaluation of Antibody-Based Targeted Delivery of Interleukin 9 in Experimental Pulmonary Hypertension.

Gouyou et al., Int J Mol Sci. 2021 Mar 27;22(7):3460

 

Cancer therapy in mice using a pure population of CD8+ T cell specific to the AH1 tumor rejection antigen.

Stringhini et al., Cancer Immunol Immunother. 2021 Nov;70(11):3183-3197

 

Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.

Olivo Pimentel Vet al., J Immunother Cancer. 2021 Mar;9(3):e001764

 

A Novel Antibody-IL15 Fusion Protein Selectively Localizes to Tumors, Synergizes with TNF-based Immunocytokine, and Inhibits Metastasis.

Corbellari et al., Mol Cancer Ther. 2021 May;20(5):859-871

 

Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.

Schliemann et al., Br J Haematol. 2021 Mar;192(6):e148-e151

 

A DNA-Encoded Chemical Library Based on Peptide Macrocycles.

Onda et al., Chemistry. 2021 Apr 26;27(24):7160-7167

 

Inference of molecular structure for characterization and improvement of clinical grade immunocytokines.

Ongaro et al., J Struct Biol. 2021 Mar;213(1):107696

 

Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells.

Russkamp et al., Exp Hematol. 2021 Mar;95:31-45

 

Antibody-based delivery of interleukin-9 to neovascular structures: Therapeutic evaluation in cancer and arthritis.

Gouyou et al., Exp Biol Med (Maywood). 2021 Apr;246(8):940-951

 

Immunotherapy with Immunocytokines and PD-1 Blockade Enhances the Anticancer Activity of Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX.

Millul et al., Mol Cancer Ther. 2021 Mar;20(3):512-522

 

Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression.

Stringhini et al., MAbs. 2021 Jan-Dec;13(1):1868066

 

A Microdosing Study with 99mTc-PHC-102 for the SPECT/CT Imaging of Primary and Metastatic Lesions in Renal Cell Carcinoma Patients.

Kulterer et al., J Nucl Med. 2021 Mar;62(3):360-365

 

2020

Discovery, affinity maturation and multimerization of small molecule ligands against human tyrosinase and tyrosinase-related protein 1.

Catalano et al., RSC Med Chem. 2020 Nov 13;12(3):363-369

 

A Single-Stranded DNA-Encoded Chemical Library Based on a Stereoisomeric Scaffold Enables Ligand Discovery by Modular Assembly of Building Blocks.

Bassi et al., Adv Sci (Weinh). 2020 Oct 14;7(22):2001970

 

An engineered 4-1BBL fusion protein with “activity on demand”.

Mock et al., Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):31780-31788

 

Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors.

Mortensen et al., .Oncotarget. 2020 Nov 3;11(44):3972-3983

 

Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors in vivo.

Nadal et al., MAbs. 2020 Jan-Dec;12(1):1836713

 

Special edition on DNA-Encoded chemical libraries.

Scheuermann et al., Biochem Biophys Res Commun. 2020 Dec 3;533(2):iii-iv

 

A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo.

Ongaro et al., Oncotarget. 2020 Oct 13;11(41):3698-3711

 

Sortase-Mediated Site-Specific Modification of Interleukin-2 for the Generation of a Tumor-Targeting Acetazolamide-Cytokine Conjugate.

Gouyou et al., ACS Omega. 2020 Sep 30;5(40):26077-26083

 

Immunocytokines are a promising immunotherapeutic approach against glioblastoma.

Weiss et al., Sci Transl Med. 2020 Oct 7;12(564):eabb2311

 

Ubiquitin Phosphorylation at Thr12 Modulates the DNA Damage Response.

Walser et al., Mol Cell. 2020 Nov 5;80(3):423-436.e9

 

An Antibody-Tumor Necrosis Factor Fusion Protein that Synergizes with Oxaliplatin for Treatment of Colorectal Cancer.

Bajic et al., Mol Cancer Ther. 2020 Dec;19(12):2554-2563

 

The targeted delivery of interleukin-12 to the carcinoembryonic antigen increases the intratumoral density of NK and CD8+ T cell in an immunocompetent mouse model of colorectal cancer.

Puca et al., J Gastrointest Oncol. 2020 Aug;11(4):803-811

 

Selective Fragments for the CREBBP Bromodomain Identified from an Encoded Self-assembly Chemical Library.

Catalano et al., .ChemMedChem. 2020 Sep 16;15(18):1752-1756

 

Complexation with a Cognate Antibody Fragment Facilitates Affinity Measurements of Fluorescein-Linked Small Molecule Ligands.

Catalano et al., Anal Chem. 2020 Aug 4;92(15):10822-10829

 

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.

Lieverse et al., BMC Cancer. 2020 Jun 15;20(1):557

 

Impact of Ligand Size and Conjugation Chemistry on the Performance of Universal Chimeric Antigen Receptor T-Cells for Tumor Killing.

Pellegrino et al., Bioconjug Chem. 2020 Jul 15;31(7):1775-1783

 

Immunotherapy of CT26 murine tumors is characterized by an oligoclonal response of tissue-resident memory T cells against the AH1 rejection antigen.

Stringhini et al., Eur J Immunol. 2020 Oct;50(10):1591-1597

 

Reflections on DNA-encoded chemical libraries.

Lerner et al., Biochem Biophys Res Commun. 2020 Jun 30;527(3):757-759

 

Comparative evaluation of DNA-encoded chemical selections performed using DNA in single-stranded or double-stranded format.

Bassi et al., Biochem Biophys Res Commun. 2020 Dec 3;533(2):223-229

 

On-DNA hit validation methodologies for ligands identified from DNA-encoded chemical libraries.

Prati et al., Biochem Biophys Res Commun. 2020 Dec 3;533(2):235-240

 

Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.

Myburgh et al., Leukemia. 2020 Oct;34(10):2688-2703

 

The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors.

Corbellari et al., Anticancer Drugs. 2020 Sep;31(8):799-805

 

Critical Evaluation of Photo-cross-linking Parameters for the Implementation of Efficient DNA-Encoded Chemical Library Selections.

Sannino et al., ACS Comb Sci. 2020 Apr 13;22(4):204-212

 

A universal reporter cell line for bioactivity evaluation of engineered cytokine products.

Mock et al., Sci Rep. 2020 Feb 24;10(1):3234

 

Quantitative and Qualitative Analysis of Humoral Immunity Reveals Continued and Personalized Evolution in Chronic Viral Infection.

Kräutler et al., Cell Rep. 2020 Jan 28;30(4):997-1012.e6

 

A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis.

Murer et al., MAbs. 2020 Jan-Dec;12(1):1714371

 

Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice.

Puca et al., J Control Release. 2020 Jan 10;317:282-290

 

 

The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors.

Puca et al., Int J Cancer. 2020 May 1;146(9):2518-2530

2019

 

Screening of copper and palladium-mediated reactions compatible with DNA-encoded chemical libraries.

Favalli et al., Helv Chim Acta. 2019 Apr 1;102(4):e1900033

 

Antibody-Mediated Delivery of VEGFC Ameliorates Experimental Chronic Colitis.

Tacconi et al., ACS Pharmacol Transl Sci. 2019 Aug 1;2(5):342-352

 

Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade.

Dakhel et al., Oncotarget. 2019 Nov 19;10(62):6678-6690

 

A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas.

De Luca Front Oncol. 2019 Nov 13;9:1228

 

DNA-Compatible Diazo-Transfer Reaction in Aqueous Media Suitable for DNA-Encoded Chemical Library Synthesis.

Gironda-Martínez et al., Org Lett. 2019 Dec 6;21(23):9555-9558

 

Automated and enhanced extraction of a small molecule-drug conjugate using an enzyme-inhibitor interaction based SPME tool followed by direct analysis by ESI-MS.

Ghiasikhou et al., Anal Bioanal Chem. 2019 Nov;411(28):7387-7398

 

A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.

Weide et al., Cancer Immunol Immunother. 2019 Sep;68(9):1547-1559

 

Design and characterisation of a novel interleukin-15 receptor alpha fusion protein and analysis of interleukin-15 complexation.

Schmid et al., PLoS One. 2019 Jul 26;14(7):e0219313

 

Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.

Hutmacher et al., Leuk Res. 2019 Sep;84:106178

 

Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.

Ziffels et al., Mol Cancer Ther. 2019 Sep;18(9):1544-1554

 

ALCAM Mediates DC Migration Through Afferent Lymphatics and Promotes Allospecific Immune Reactions.

Willrodt et al., Front Immunol. 2019 Apr 12;10:759

 

Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.

Murer et al., N Biotechnol. 2019 Sep 25;52:42-53

 

A Focused DNA-Encoded Chemical Library for the Discovery of Inhibitors of NAD+-Dependent Enzymes.

Yuen et al., J Am Chem Soc. 2019 Apr 3;141(13):5169-5181

 

A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.

Akkapeddi et al., Leukemia. 2019 Sep;33(9):2155-2168

 

Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.

Neri, Cancer Immunol Res. 2019 Mar;7(3):348-354

 

Advances in antibody engineering for rheumatic diseases.

Schmid et al., Nat Rev Rheumatol. 2019 Apr;15(4):197-207

 

Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells.

Hutmacher et al., Cancer Immunol Res. 2019 Apr;7(4):572-583

 

A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors.

Ongaro et al., J Biotechnol. 2019 Feb 10;291:17-25

 

Targeted delivery of calreticulin to ED-A fibronectin leads to tumor-growth retardation.

Ziffels et al., J Biotechnol. 2019 Jan 20;290:53-58

 

F8-IL10: A New Potential Antirheumatic Drug Evaluated by a PET-Guided Translational Approach.

Bruijnen et al., Mol Pharm. 2019 Jan 7;16(1):273-281

 

Quantitative Assessment of Affinity Selection Performance by Using DNA-Encoded Chemical Libraries.

Sannino et al., Chembiochem. 2019 Apr 1;20(7):955-962

 

Targeted Delivery of TNF Potentiates the Antibody-Dependent Cell-Mediated Cytotoxicity of an Anti-Melanoma Immunoglobulin.

Murer et al., J Invest Dermatol. 2019 Jun;139(6):1339-1348

 

Antibody-based Delivery of TNF to the Tumor Neovasculature Potentiates the Therapeutic Activity of a Peptide Anticancer Vaccine.

Probst et al., Clin Cancer Res. 2019 Jan 15;25(2):698-709

 

Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.

Hutmacher et al., Adv Drug Deliv Rev. 2019 Feb 15;141:67-91

2018

 

In Vivo Antitumor Activity of a Novel Acetazolamide-Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas.

Cazzamalli et al., ACS Omega. 2018 Nov 30;3(11):14726-14731

 

Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation.

Schwager et al., JCI Insight. 2018 Dec 6;3(23):e124850

 

Affinity Enhancement of Protein Ligands by Reversible Covalent Modification of Neighboring Lysine Residues.

Dal Corso et al., Angew Chem Int Ed Engl. 2018 Dec 21;57(52):17178-17182

 

A novel dual-cytokine-antibody fusion protein for the treatment of CD38-positive malignancies.

De Luca et al., Protein Eng Des Sel. 2018 May 1;31(5):173-179

 

Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.

De Luca et al., Cancer Immunol Immunother. 2018 Sep;67(9):1381-1391

 

Targeting the extradomain A of fibronectin allows identification of vascular resistance to antiangiogenic therapy in experimental glioma.

Acker et al., Oncotarget. 2018 Jun 12;9(45):27760-27772

 

A DNA-Encoded Library of Chemical Compounds Based on Common Scaffolding Structures Reveals the Impact of Ligand Geometry on Protein Recognition.

Favalli et al., ChemMedChem. 2018 Jul 6;13(13):1303-1307

 

Covalent linkage of the DNA repair template to the CRISPR-Cas9 nuclease enhances homology-directed repair.

Savic et al., Elife. 2018 May 29;7:e33761

 

Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.

Cazzamalli et al., Clin Cancer Res. 2018 Aug 1;24(15):3656-3667

 

DNA-encoded chemical libraries – achievements and remaining challenges.

Favalli et al., FEBS Lett. 2018 Jun;592(12):2168-2180

 

The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses.

Rekers et al., Oncoimmunology. 2018 Jan 16;7(4):e1414119

 

Versatile protein recognition by the encoded display of multiple chemical elements on a constant macrocyclic scaffold.

Li et al., Nat Chem. 2018 Apr;10(4):441-448

 

Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.

Schmid et al., J Biotechnol. 2018 Apr 10;271:29-36

 

Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity.

Ziffels et al., Immunotherapy. 2018 Mar;10(3):177-188

 

Antibody-based targeted delivery of interleukin-4 synergizes with dexamethasone for the reduction of inflammation in arthritis.

Schmid et al., Rheumatology (Oxford). 2018 Apr 1;57(4):748-755

 

Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.

Cazzamalli et al., J Am Chem Soc. 2018 Feb 7;140(5):1617-1621

 

DNA-Encoded Chemical Libraries: A Selection System Based on Endowing Organic Compounds with Amplifiable Information.

Neri et al., Annu Rev Biochem. 2018 Jun 20;87:479-502

 

Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.

Menssen et al., J Cancer Res Clin Oncol. 2018 Mar;144(3):499-507

 

Membranal and Blood-Soluble HLA Class II Peptidome Analyses Using Data-Dependent and Independent Acquisition.

Ritz et al., Proteomics. 2018 Jun;18(12):e1700246

2017

Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments.

Cazzamalli et al., Chimia (Aarau). 2017 Oct 25;71(10):712-715

 

Impact of a Central Scaffold on the Binding Affinity of Fragment Pairs Isolated from DNA-Encoded Self-Assembling Chemical Libraries.

Bigatti et al., ChemMedChem. 2017 Nov 8;12(21):1748-1752

 

A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo.

Dal Corso et al., .J Control Release. 2017 Oct 28;264:211-218

 

Data-Independent Acquisition of HLA Class I Peptidomes on the Q Exactive Mass Spectrometer Platform.

Ritz et al., Proteomics. 2017 Oct;17(19):10.1002/pmic.201700177

 

Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.

De Luca et al., Mol Cancer Ther. 2017 Nov;16(11):2442-2451

 

Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.

Dal Corso et al., Bioconjug Chem. 2017 Jul 19;28(7):1826-1833

 

A Specific and Covalent JNK-1 Ligand Selected from an Encoded Self-Assembling Chemical Library.

Zimmermann et al., Chemistry. 2017 Jun 16;23(34):8152-8155

 

 

Sarcoma Eradication by Doxorubicin and Targeted TNF Relies upon CD8+ T-cell Recognition of a Retroviral Antigen.

Probst et al., Cancer Res. 2017 Jul 1;77(13):3644-3654

 

Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma.

Robl et al., Transl Oncol. 2017 Jun;10(3):419-430

 

Twenty-five Years of DNA-Encoded Chemical Libraries.

Neri, Chembiochem. 2017 May 4;18(9):827-828

 

Quantitative PCR is a Valuable Tool to Monitor the Performance of DNA-Encoded Chemical Library Selections.

Li et al., Chembiochem. 2017 May 4;18(9):848-852

 

Intralesional treatment of metastatic melanoma: a review of therapeutic options.

Weide et al., Cancer Immunol Immunother. 2017 May;66(5):647-656

 

Hit-Validation Methodologies for Ligands Isolated from DNA-Encoded Chemical Libraries.

Zimmermann et al., Chembiochem. 2017 May 4;18(9):853-857

 

The MHC Class II Immunopeptidome of Lymph Nodes in Health and in Chemically Induced Colitis.

Fugmann et al., J Immunol. 2017 Feb 1;198(3):1357-1364

 

Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.

Gébleux et al., Int J Cancer. 2017 Apr 1;140(7):1670-1679

 

Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.

Cazzamalli et al., J Control Release. 2017 Jan 28;246:39-45

 

Purification of soluble HLA class I complexes from human serum or plasma deliver high quality immuno peptidomes required for biomarker discovery.

Ritz et al., .Proteomics. 2017 Jan;17(1-2):10.1002/pmic.201600364

2016

Lung tissue remodelling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and changes in extracellular matrix and fibrosis associated gene expression.

Franz et al., Oncotarget. 2016 Dec 6;7(49):81241-81254

 

A Small-Molecule Inhibitor of Lin28.

Roos et al., ACS Chem Biol. 2016 Oct 21;11(10):2773-2781

 

Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.

Gloger et al., Cancer Immunol Immunother. 2016 Nov;65(11):1377-1393

 

Detection of Soluble ED-A(+) Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling.

Ziffels et al., Dis Markers. 2016;2016:3695454

 

Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma.

Cazzamalli et al., Mol Cancer Ther. 2016 Dec;15(12):2926-2935

 

Antibody-Based Targeted Delivery of Interleukin-22 Promotes Rapid Clinical Recovery in Mice With DSS-Induced Colitis.

Bootz et al., Inflamm Bowel Dis. 2016 Sep;22(9):2098-105

 

DNA-encoded chemical libraries: foundations and applications in lead discovery.

Zimmermann et al., Drug Discov Today. 2016 Nov;21(11):1828-1834

 

Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins.

Venetz et al., J Biol Chem. 2016 Aug 26;291(35):18139-47

 

Optimized Reaction Conditions for Amide Bond Formation in DNA-Encoded Combinatorial Libraries.

Li et al., ACS Comb Sci. 2016 Aug 8;18(8):438-43

 

Immunocytokines for cancer treatment: past, present and future.

Neri et al., Curr Opin Immunol. 2016 Jun;40:96-102

 

 

High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients’ sera.

Ritz et al., Proteomics. 2016 May;16(10):1570-80

 

Automated screening for small organic ligands using DNA-encoded chemical libraries.

Decurtins et al., Nat Protoc. 2016 Apr;11(4):764-80

 

Identification of E-cadherin signature motifs functioning as cleavage sites for Helicobacter pylori HtrA.

Schmidt et al., Sci Rep. 2016 Mar 17;6:23264

 

Targeted IL-4 therapy synergizes with dexamethasone to induce a state of tolerance by promoting Treg cells and macrophages in mice with arthritis.

Kawalkowska et al., Eur J Immunol. 2016 May;46(5):1246-57

 

A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.

Krall et al., J Nucl Med. 2016 Jun;57(6):943-9

 

Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site.

Kiefer et al., Immunol Rev. 2016 Mar;270(1):178-92

 

Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.

Bootz et al., Drug Discov Today. 2016 Jan;21(1):180-189

 

High-resolution analysis of the murine MHC class II immunopeptidome.

Sofron et al., Eur J Immunol. 2016 Feb;46(2):319-28

2015

Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates.

Gébleux et al., Mol Cancer Ther. 2015 Nov;14(11):2606-12

 

Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model.

Rekers et al., Radiother Oncol. 2015 Sep;116(3):438-42

 

“Cap-and-Catch” Purification for Enhancing the Quality of Libraries of DNA Conjugates.

Franzini et al., ACS Comb Sci. 2015 Jul 13;17(7):393-8

 

Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents.

Casi et al., J Med Chem. 2015 Nov 25;58(22):8751-61

 

Tankyrase 1 Inhibitors with Drug-like Properties Identified by Screening a DNA-Encoded Chemical Library.

Samain et al., J Med Chem. 2015 Jun 25;58(12):5143-9

 

Targeted delivery of interleukin-10 to chronic cardiac allograft rejection using a human antibody specific to the extra domain A of fibronectin.

Franz et al., Int J Cardiol. 2015 Sep 15;195:311-22

 

Imaging T Cells In Vivo.

Neri, J Nucl Med. 2015 Aug;56(8):1135-6 

Alternatively Spliced EDA Domain of Fibronectin Is a Target for Pharmacodelivery Applications in Inflammatory Bowel Disease.

Bootz et al., Inflamm Bowel Dis. 2015 Aug;21(8):1908-17

 

Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids.

Bujak et al., Invest New Drugs. 2015 Aug;33(4):791-800

 

Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.

Danielli et al., Cancer Immunol Immunother. 2015 Aug;64(8):999-1009

 

Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature.

Börschel et al., Leuk Res. 2015 Jul;39(7):739-48

 

Editorial overview: Next generation therapeutics: Creating and exploiting the chemistry of large numbers.

Scheuermann et al., Curr Opin Chem Biol. 2015 Jun;26:iv-v

 

The Targeted Delivery of Interleukin 4 Inhibits Development of Endometriotic Lesions in a Mouse Model.

Quattrone et al., Reprod Sci. 2015 Sep;22(9):1143-52

 

Interrogating target-specificity by parallel screening of a DNA-encoded chemical library against closely related proteins.

Franzini et al., Chem Commun (Camb). 2015 May 11;51(38):8014-6

 

Dual-pharmacophore DNA-encoded chemical libraries.

Scheuermann et al., Curr Opin Chem Biol. 2015 Jun;26:99-103

 

Noninternalizing targeted cytotoxics for cancer therapy.

Casi et al., Mol Pharm. 2015 Jun 1;12(6):1880-4

 

The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.

Hess et al., Cancer Immunol Immunother. 2015 May;64(5):635-44

 

Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation.

Wichert et al., Nat Chem. 2015 Mar;7(3):241-9

 

Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.

Wieckowski et al., Lung Cancer. 2015 Apr;88(1):9-15

 

Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

Schliemann et al., Cancer Immunol Res. 2015 May;3(5):547-56

 

Identification of structure-activity relationships from screening a structurally compact DNA-encoded chemical library.

Franzini et al., Angew Chem Int Ed Engl. 2015 Mar 23;54(13):3927-31

 

Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies.

Venetz et al., Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2000-5

 

The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.

Catania et al., Cell Adh Migr. 2015;9(1-2):14-21

 

Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.

Zegers et al., Clin Cancer Res. 2015 Mar 1;21(5):1151-60

 

Armed antibodies for cancer treatment: a promising tool in a changing era.

Danielli et al., Cancer Immunol Immunother. 2015 Jan;64(1):113-21

2014

A chemically defined trifunctional antibody-cytokine-drug conjugate with potent antitumor activity.

List et al., Mol Cancer Ther. 2014 Nov;13(11):2641-52

 

Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation.

Hemmerle et al., J Dermatol Sci. 2014 Nov;76(2):96-103

 

Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis.

Hemmerle et al., Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12008-12

 

A fibrin-specific monoclonal antibody from a designed phage display library inhibits clot formation and localizes to tumors in vivo.

Putelli et al., J Mol Biol. 2014 Oct 23;426(21):3606-18

 

Systematic evaluation and optimization of modification reactions of oligonucleotides with amines and carboxylic acids for the synthesis of DNA-encoded chemical libraries.

Franzini et al., Bioconjug Chem. 2014 Aug 20;25(8):1453-61

 

Limited efficacy of intratumoral IL-2 applied to large melanoma metastases.

Weide et al., Cancer Immunol Immunother. 2014 Nov;63(11):1231-2

 

A highly functional synthetic phage display library containing over 40 billion human antibody clones.

Weber et al., PLoS One. 2014 Jun 20;9(6):e100000

 

Monoclonal antibodies to murine thrombospondin-1 and thrombospondin-2 reveal differential expression patterns in cancer and low antigen expression in normal tissues.

Bujak et al., Exp Cell Res. 2014 Sep 10;327(1):135-45

 

Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.

Weide et al., Cancer Immunol Res. 2014 Jul;2(7):668-78

 

 

Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.

Pretto et al., Cancer Immunol Immunother. 2014 Sep;63(9):901-10

 

Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications.

Hess et al., Exp Biol Med (Maywood). 2014 Jul;239(7):842-852

 

Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.

Hess et al., Protein Eng Des Sel. 2014 Jun;27(6):207-13

 

The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo.

Hemmerle et al., Cancer Immunol Res. 2014 Jun;2(6):559-67

 

De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection.

Franz et al., J Mol Histol. 2014 Oct;45(5):519-32

 

Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice.

Gutbrodt et al., Mol Cancer Ther. 2014 Jul;13(7):1772-6

 

DNA-encoded chemical libraries: advancing beyond conventional small-molecule libraries.

Franzini et al., Acc Chem Res. 2014 Apr 15;47(4):1247-55

 

Recent advances in osteosarcoma.

Botter et al., Curr Opin Pharmacol. 2014 Jun;16:15-23

 

From target discovery to clinical trials with armed antibody products.

Elia et al., J Proteomics. 2014 Jul 31;107:50-5

 

A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors.

Krall et al., Angew Chem Int Ed Engl. 2014 Apr 14;53(16):4231-5

 

Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids.

Perrino et al., Cancer Res. 2014 May 1;74(9):2569-78

 

 

Reformatting of scFv antibodies into the scFv-Fc format and their downstream purification.

Bujak et al., Methods Mol Biol. 2014;1131:315-34

 

A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development.

Strassberger et al., J Proteomics. 2014 Mar 17;99:138-51

 

Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin’s lymphoma.

Aloj et al., Eur J Nucl Med Mol Imaging. 2014 May;41(5):867-77

 

Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily.

Hemmerle et al., J Biotechnol. 2014 Feb 20;172:73-6

 

A human monoclonal antibody specific to placental alkaline phosphatase, a marker of ovarian cancer.

Ravenni et al., MAbs. 2014 Jan-Feb;6(1):86-94

 

Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of (131)I-L19SIP in a prostate cancer patient.

Locher et al., J Cancer Res Clin Oncol. 2014 Jan;140(1):35-43

 

The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.

Hemmerle et al., Int J Cancer. 2014 Jan 15;134(2):467-77

2013

Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study.

Poli et al., Cancer Immunol Res. 2013 Aug;1(2):134-43

 

Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse.

Doll et al., Arthritis Res Ther. 2013 Sep 27;15(5):R138

 

Site-specific chemical modification of antibody fragments using traceless cleavable linkers.

Bernardes et al., Nat Protoc. 2013 Nov;8(11):2079-89

 

Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.

Gutbrodt et al., Sci Transl Med. 2013 Sep 4;5(201):201ra118

 

Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B⁺ tenascin-C and ED-A⁺ fibronectin in dilated cardiomyopathy: potential impact on disease progression and patients’ prognosis.

Franz et al., Int J Cardiol. 2013 Oct 15;168(6):5344-51

 

Immunocytokines: a review of molecules in clinical development for cancer therapy.

List et al., Clin Pharmacol. 2013 Aug 20;5(Suppl 1):29-45

 

Pharmacotherapy of metastatic melanoma: emerging trends and opportunities for a cure.

Pretto et al., Pharmacol Ther. 2013 Sep;139(3):405-11

 

Selective imaging of chronic cardiac rejection using a human antibody specific to the alternatively spliced EDA domain of fibronectin.

Franz et al., J Heart Lung Transplant. 2013 Jun;32(6):641-50

 

Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications.

Steiner et al., Bioconjug Chem. 2013 Feb 20;24(2):234-41

 

Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients.

Heuveling et al., J Nucl Med. 2013 Mar;54(3):397-401

 

Small targeted cytotoxics: current state and promises from DNA-encoded chemical libraries.

Krall et al., Angew Chem Int Ed Engl. 2013 Jan 28;52(5):1384-402

 

The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.

Schwager et al., J Invest Dermatol. 2013 Mar;133(3):751-758

 

Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma.

Papadia et al., J Surg Oncol. 2013 Feb;107(2):173-9

2012

Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site.

List et al., MAbs. 2012 Nov-Dec;4(6):775-83

 

A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data.

Hemmerle et al., Protein Eng Des Sel. 2012 Dec;25(12):851-4

 

Sequence determinants of a microtubule tip localization signal (MtLS).

Buey et al., J Biol Chem. 2012 Aug 17;287(34):28227-42

 

The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.

Pasche et al., Clin Cancer Res. 2012 Aug 1;18(15):4092-103

 

Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format.

Zuberbühler et al., Chem Commun (Camb). 2012 Jul 18;48(56):7100-2

 

Discovery of small-molecule interleukin-2 inhibitors from a DNA-encoded chemical library.

Leimbacher et al., Chemistry. 2012 Jun 18;18(25):7729-37

 

Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies.

Erba et al., J Nucl Med. 2012 Jun;53(6):922-7

 

Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery.

Casi et al., J Am Chem Soc. 2012 Apr 4;134(13):5887-92

 

Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts.

Moschetta et al., Cancer Res. 2012 Apr 1;72(7):1814-24

 

Selection and characterization of human antibody fragments specific for psoriasin – a cancer associated protein.

Cyranka-Czaja et al., Biochem Biophys Res Commun. 2012 Mar 9;419(2):250-5

 

Antibody-drug conjugates: basic concepts, examples and future perspectives.

Casi et al., J Control Release. 2012 Jul 20;161(2):422-8

 

Immunocytokines: a novel class of potent armed antibodies.

Pasche et al., Drug Discov Today. 2012 Jun;17(11-12):583-90

 

A traceless vascular-targeting antibody-drug conjugate for cancer therapy.

Bernardes et al., Angew Chem Int Ed Engl. 2012 Jan 23;51(4):941-4

 

Chronic cardiac allograft rejection: critical role of ED-A(+) fibronectin and implications for targeted therapy strategies.

Franz et al., J Pathol. 2012 Mar;226(4):557-61

 

Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery.

Galler et al., Histochem Cell Biol. 2012 Feb;137(2):195-204

 

The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate.

Pasche et al., Angiogenesis. 2012 Mar;15(1):165-9

2011

20 years of DNA-encoded chemical libraries.

Mannocci et al., Chem Commun (Camb). 2011 Dec 28;47(48):12747-53

 

A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.

Eigentler et al., Clin Cancer Res. 2011 Dec 15;17(24):7732-42

 

Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends.

Steiner et al., Clin Cancer Res. 2011 Oct 15;17(20):6406-16

 

Interfering with pH regulation in tumours as a therapeutic strategy.

Neri et al., Nat Rev Drug Discov. 2011 Sep 16;10(10):767-77

 

The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model.

Schwager et al., Hum Reprod. 2011 Sep;26(9):2344-52

 

Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions.

Frey et al., Exp Dermatol. 2011 Aug;20(8):685-8

 

A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer.

Schwager et al., Head Neck Oncol. 2011 May 8;3:25

 

Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy.

Fugmann et al., Kidney Int. 2011 Aug;80(3):272-81

 

Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7.

Pasche et al., J Biotechnol. 2011 Jun 10;154(1):84-92

 

A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin.

Villa et al., MAbs. 2011 May-Jun;3(3):264-72

 

Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis.

Baldinger et al., Histochem Cell Biol. 2011 May;135(5):427-41

 

Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies.

Czabanka et al., Eur J Cancer. 2011 May;47(8):1276-84

 

The accessible cerebral vascular proteome in a mouse model of cerebral β-amyloidosis.

Roesli et al., J. Proteomics. 2011 Apr 1;74(4):539-46

 

Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.

Frey et al., Integr Biol (Camb). 2011 Apr;3(4):468-78

 

Selection of Carbonic Anhydrase IX Inhibitors from One Million DNA-Encoded Compounds.

Buller et al., ACS Chem Biol. 2011 Apr 15;6(4):336-44

 

Comparative in vivo analysis of the atherosclerotic plaque targeting properties of eight human monoclonal antibodies.

Fiechter et al., Atherosclerosis. 2011 Feb;214(2):325-30

 

Expression of extra domain A containing fibronectin in chronic cardiac allograft rejection.

Franz et al., J Heart Lung Transplant. 2011 Jan;30(1):86-94

2010

The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma.

Frey et al., J Urol. 2010 Dec;184(6):2540-8

 

In vivo imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography.

Mumprecht et al., Cancer Res. 2010 Nov 1;70(21):8842-51

 

A novel reactive ester derivative of biotin with reduced membrane permeability for in vivo biotinylation experiments.

Strassberger et al., Proteomics. 2010 Oct;10(19):3544-8

 

Isolation of potent and specific trypsin inhibitors from a DNA-encoded chemical library.

Mannocci et al., Bioconjug Chem. 2010 Oct 20;21(10):1836-41

 

The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

Johannsen et al., Eur J Cancer. 2010 Nov;46(16):2926-35

 

Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3.

Rinderknecht et al., PLoS One. 2010 Aug 2;5(8):e11941

 

Drug discovery with DNA-encoded chemical libraries.

Buller et al., Bioconjug Chem. 2010 Sep 15;21(9):1571-80

 

Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.

Sommavilla et al., Protein Eng Des Sel. 2010 Aug;23(8):653-61

 

Methods for the identification of vascular markers in health and disease: from the bench to the clinic.

Roesli et al., J Proteomics. 2010 Oct 10;73(11):2219-29

 

 

High-throughput sequencing for the identification of binding molecules from DNA-encoded chemical libraries.

Buller et al., Bioorg Med Chem Lett. 2010 Jul 15;20(14):4188-92

 

Chemical proteomic and bioinformatic strategies for the identification and quantification of vascular antigens in cancer.

Strassberger et al., J Proteomics. 2010 Sep 10;73(10):1954-73

 

DeepQuanTR: MALDI-MS-based label-free quantification of proteins in complex biological samples.

Fugmann et al., Proteomics. 2010 Jul;10(14):2631-43

 

Tumour-targeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3.

Pfaffen et al., Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1559-65

 

DNA-encoded chemical libraries: a tool for drug discovery and for chemical biology.

Scheuermann et al., Chembiochem. 2010 May 3;11(7):931-7

 

A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies.

Berndt et al., Histochem Cell Biol. 2010 Apr;133(4):467-75

 

Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies.

Franz et al., J Mol Histol. 2010 Feb;41(1):39-50

 

Isolation of a small-molecule inhibitor of the antiapoptotic protein Bcl-xL from a DNA-encoded chemical library.

Melkko et al., ChemMedChem. 2010 Apr 6;5(4):584-90

 

A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation.

Schwarz et al., Nat Chem Biol. 2010 Apr;6(4):264-6

 

Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA.

Sgier et al., Protein Eng Des Sel. 2010 Apr;23(4):261-9

 

Site-specific and stoichiometric conjugation of cationic porphyrins to antiangiogenic monoclonal antibodies.

Alonso et al., Bioconjug Chem. 2010 Feb 17;21(2):302-13

 

Antibody-based vascular tumor targeting.

Schliemann et al., Recent Results Cancer Res. 2010;180:201-16

 

A proteomic approach for the identification of vascular markers of liver metastasis.

Borgia et al., Cancer Res. 2010 Jan 1;70(1):309-18

 

Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3.

Pfaffen et al., Exp Cell Res. 2010 Mar 10;316(5):836-47

 

In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy.

Schliemann et al., Blood. 2010 Jan 21;115(3):736-44

 

Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies.

Pedretti et al., Atherosclerosis. 2010 Feb;208(2):382-9

2009

New strategy for the extension of the serum half-life of antibody fragments.

Trüssel et al., Bioconjug Chem. 2009 Dec;20(12):2286-92

 

Discovery of TNF inhibitors from a DNA-encoded chemical library based on diels-alder cycloaddition.

Buller et al., Chem Biol. 2009 Oct 30;16(10):1075-86

 

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis.

Schwager et al., Arthritis Res Ther. 2009;11(5):R142

 

Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma.

Schliemann et al., Leuk Res. 2009 Dec;33(12):1718-22

 

In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives.

Ahlskog et al., Bioorg Med Chem Lett. 2009 Aug 15;19(16):4851-6

 

Next generation therapeutics.

Altmann et al., Curr Opin Chem Biol. 2009 Jun;13(3):231-4

 

Encoding chemistry.

Neri et al., Nat Chem Biol. 2009 Jul;5(7):452-3

 

Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells.

Roesli et al., Cancer Res. 2009 Jul 1;69(13):5406-14

 

B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?

Richter et al., J Cancer Res Clin Oncol. 2009 Oct;135(10):1351-8

 

(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.

Tijink et al., Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1235-44

 

Improved protein sequence coverage by on resin deglycosylation and cysteine modification for biomarker discovery.

Kamada et al., Proteomics. 2009 Feb;9(3):783-7

 

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients.

Sauer et al., Blood. 2009 Mar 5;113(10):2265-74

 

A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells.

Zuberbühler et al., Protein Eng Des Sel. 2009 Mar;22(3):169-74

 

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2.

Schliemann et al., Blood. 2009 Mar 5;113(10):2275-83

 

Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer.

Pedretti et al., Lung Cancer. 2009 Apr;64(1):28-33.

2008

High-throughput sequencing allows the identification of binding molecules isolated from DNA-encoded chemical libraries.

Mannocci et al., Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17670-5

 

Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy.

Mårlind et al., Clin Cancer Res. 2008 Oct 15;14(20):6515-24

 

Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis.

Conrotto et al., Int J Cancer. 2008 Dec 15;123(12):2856-64

 

Design and synthesis of a novel DNA-encoded chemical library using Diels-Alder cycloadditions.

Buller et al., Bioorg Med Chem Lett. 2008 Nov 15;18(22):5926-31

 

A portable albumin binder from a DNA-encoded chemical library.

Dumelin et al., Angew Chem Int Ed Engl. 2008;47(17):3196-201

 

Quantitative recovery of biotinylated proteins from streptavidin-based affinity chromatography resins.

Rösli et al., Methods Mol Biol. 2008;418:89-100

 

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.

Villa et al., Int J Cancer. 2008 Jun 1;122(11):2405-13

 

DNA-encoded chemical libraries for the discovery of MMP-3 inhibitors.

Scheuermann et al., Bioconjug Chem. 2008 Mar;19(3):778-85

 

Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping.

Roesli et al., FASEB J. 2008 Jun;22(6):1933-44

2007

The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases.

Rybak et al., Cancer Res. 2007 Nov 15;67(22):10948-57

 

Antibody-based targeting of the tumor vasculature.

Schliemann et al., Biochim Biophys Acta. 2007 Dec;1776(2):175-92

 

Lead discovery by DNA-encoded chemical libraries.

Melkko et al., Drug Discov Today. 2007 Jun;12(11-12):465-71

 

The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis.

Kaspar et al., Cancer Res. 2007 May 15;67(10):4940-8

 

Isolation of high-affinity trypsin inhibitors from a DNA-encoded chemical library.

Melkko et al., Angew Chem Int Ed Engl. 2007;46(25):4671-4

 

Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment.

Birchler et al., Otolaryngol Head Neck Surg. 2007 Apr;136(4):543-8

 

Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis.

Wyss et al., J Nucl Med. 2007 Apr;48(4):608-14

 

Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo.

von Lukowicz et al., J Nucl Med. 2007 Apr;48(4):582-7

 

Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method.

Castronovo et al., Proteomics. 2007 Apr;7(8):1188-96

 

Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis.

Trachsel et al., Arthritis Res Ther. 2007;9(1):R9

 

Selection of single domain binding proteins by covalent DNA display.

Bertschinger et al., Protein Eng Des Sel. 2007 Feb;20(2):57-68

 

A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo.

Trachsel et al., J Invest Dermatol. 2007 Apr;127(4):881-6

 

 

Ligand-based vascular targeting of disease.

Rybak et al., ChemMedChem. 2007 Jan;2(1):22-40

 

A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties.

Grabulovski et al., J Biol Chem. 2007 Feb 2;282(5):3196-204

2006

In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature.

Roesli et al., Nat Protoc. 2006;1(1):192-9

 

Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments.

Berndorff et al., J Nucl Med. 2006 Oct;47(10):1707-16

 

Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo.

Silacci et al., Protein Eng Des Sel. 2006 Oct;19(10):471-8

 

Efforts toward the total synthesis of tubulysins: new hopes for a more effective targeted drug delivery to tumors.

Neri et al., ChemMedChem. 2006 Feb;1(2):175-80

 

A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer.

Castronovo et al., Mol Cell Proteomics. 2006 Nov;5(11):2083-91

 

DNA-encoded chemical libraries.

Scheuermann et al., J Biotechnol. 2006 Dec 1;126(4):568-81

 

Recombinant antibodies for the depletion of abundant proteins from human serum.

Ettorre et al., Proteomics. 2006 Aug;6(16):4496-505

 

Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19).

Spaeth et al., Nucl Med Biol. 2006 Jul;33(5):661-6

 

An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties.

Gafner et al., Int J Cancer. 2006 Nov 1;119(9):2205-12

 

Antibodies for angiogenesis inhibition, vascular targeting and endothelial cell transcytosis.

Trachsel et al., Epub 2006 May 20

 

Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.

Tijink et al., J Nucl Med. 2006 Jul;47(7):1127-35

 

Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.

Berndt et al., J Cancer Res Clin Oncol. 2006 Aug;132(8):537-46

 

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

Brack et al., Clin Cancer Res. 2006 May 15;12(10):3200-8

 

Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin.

Balza et al., Clin Cancer Res. 2006 Apr 15;12(8):2575-82

 

Selection of streptavidin binders from a DNA-encoded chemical library.

Dumelin et al., Bioconjug Chem. 2006 Mar-Apr;17(2):366-70

 

On the magnitude of the chelate effect for the recognition of proteins by pharmacophores scaffolded by self-assembling oligonucleotides.

Melkko et al., Chem Biol. 2006 Feb;13(2):225-31

 

Two-dimensional mass spectrometric mapping.

Roesli et al., Curr Opin Chem Biol. 2006 Feb;10(1):35-41

 

Fibronectin as target for tumor therapy.

Kaspar et al., Int J Cancer. 2006 Mar 15;118(6):1331-9

 

Selective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugate.

Fabbrini et al., Int J Cancer. 2006 Apr 1;118(7):1805-13

2004

Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin.

Matter et al., Circ Res. 2004 Dec 10;95(12):1225-33

 

Covalent DNA display as a novel tool for directed evolution of proteins in vitro.

Bertschinger et al., Protein Eng Des Sel. 2004 Sep;17(9):699-707

 

Molecular targeting of angiogenesis for imaging and therapy.

Brack et al., Eur J Nucl Med Mol Imaging. 2004 Sep;31(9):1327-41

 

Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution.

Rybak et al., Proteomics. 2004 Aug;4(8):2296-9

 

 

Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study.

Scheurer et al., Proteomics. 2004 Jun;4(6):1737-60

 

Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.

Heinis et al., Biochemistry. 2004 May 25;43(20):6293-303

 

Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis.

Ebbinghaus et al., Curr Pharm Des. 2004;10(13):1537-49

 

Encoded self-assembling chemical libraries.

Melkko et al., Nat Biotechnol. 2004 May;22(5):568-74

 

Molecular targeting of angiogenesis.

Alessi et al., Biochim Biophys Acta. 2004 Mar 4;1654(1):39-49

2003

Targeting the vascular endothelium–novel approaches.

Neri, Pathophysiol Haemost Thromb. 2003;33 Suppl 1:7-8

 

Selective targeted delivery of TNFalpha to tumor blood vessels.

Borsi et al., Blood. 2003 Dec 15;102(13):4384-92

 

Proteomics application exercise of the Swiss Proteomics Society: report of the SPS’02 session.

Binz et al., Proteomics. 2003 Aug;3(8):1562-6

 

Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors.

Birchler et al., Laryngoscope. 2003 Jul;113(7):1231-7

 

Calmodulin-tagged phage and two-filter sandwich assays for the identification of enzymatic activities.

Heinis et al., Methods Mol Biol. 2003;230:313-28

 

Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.

Halin et al., Cancer Res. 2003 Jun 15;63(12):3202-10

 

Modulation of gene expression by extracellular pH variations in human fibroblasts: a transcriptomic and proteomic study.

Bumke et al., Proteomics. 2003 May;3(5):675-88

 

Unexpected observation of concentration-dependent dissociation rates for antibody-antigen complexes and other macromolecular complexes in competition experiments.

Scheuermann et al., J Immunol Methods. 2003 May 1;276(1-2):129-34

 

Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer.

Santimaria et al., Clin Cancer Res. 2003 Feb;9(2):571-9

 

Expression of extradomain-B-containing fibronectin in subretinal choroidal neovascular membranes.

Nicolò et al., Am J Ophthalmol. 2003 Jan;135(1):7-13

 

Calmodulin as an affinity purification tag.

Melkko et al., Methods Mol Biol. 2003;205:69-77

 

Activation of T cells via tumor antigen specific chimeric receptors: the role of the intracellular signaling domain.

Losch et al., Int J Cancer. 2003 Jan 20;103(3):399-407